Zura Bio Limited
General ticker "ZURA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $517.3M (TTM average)
Zura Bio Limited follows the US Stock Market performance with the rate: 23.8%.
Estimated limits based on current volatility of 4.0%: low 5.03$, high 5.45$
Factors to consider:
- Total employees count: 40 (+33.3%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Going concern doubt, IP disputes, Failure to achieve profitability, Dev failure, Capital raising
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.60$, 6.64$]
- 2026-12-31 to 2027-12-31 estimated range: [1.83$, 4.86$]
Financial Metrics affecting the ZURA estimates:
- Positive: with PPE of -4.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Investing cash flow per share per price, % of -0.02 <= 2.08
- Negative: negative Industry operating cash flow (median)
- Negative: 0 < Industry inventory ratio change (median), % of 0
Short-term ZURA quotes
Long-term ZURA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $62.64MM | $55.19MM | $75.25MM |
| Operating Income | $-62.64MM | $-55.19MM | $-75.25MM |
| Non-Operating Income | $2.08MM | $2.79MM | $6.60MM |
| R&D Expense | $44.00MM | $24.40MM | $42.08MM |
| Income(Loss) | $-60.56MM | $-52.40MM | $-68.65MM |
| Net Income(Loss)* | $-60.36MM | $-52.40MM | $-68.65MM |
| Stockholders Equity | $59.33MM | $146.81MM | $101.54MM |
| Assets | $100.84MM | $179.53MM | $113.95MM |
| Operating Cash Flow | $-15.05MM | $-28.08MM | $-64.81MM |
| Capital expenditure | $8.00MM | $0.07MM | $0.11MM |
| Investing Cash Flow | $-8.00MM | $-5.08MM | $-0.11MM |
| Financing Cash Flow | $121.29MM | $109.84MM | $-2.16MM |
| Earnings Per Share** | $-1.83 | $-0.70 | $-0.73 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.